A Revolutionary Approach to Gene Therapy

The Future of Genomic Medicine and Precision Diagnostics
On Feb 29
Rare Disease Day
Canary is Committed to Developing Next Gen Treatments for Diseases that Impact 300 Million People Globally.
Our Mission
To harness the transformative power of gene therapy and AI-driven precision diagnostics to revolutionize healthcare and empower individuals to live healthier, longer lives.
Company Overview
Therapeutics

Next Generation Gene Therapy with Novel Vectors

Therapeutics

LNP-mRNA Therapies Guided by Precision Nanoantibodies

Diagnostics

Precision Dx Designed to Support Gene Therapy

Revolutionizing Gene Therapy with Powerful Novel Vectors

Revolutionizing Gene Therapy with Powerful Novel Vectors

Neurological disorders affect nearly 1 billion people worldwide, and many of these conditions are currently untreatable. Traditional therapies often fall short in addressing the underlying causes of these debilitating diseases, leaving patients and their families with limited options and dwindling hope.
At Canary, we are pioneering a transformative approach to gene therapy, harnessing the power of next-gen non-viral vectors and adeno-associated viruses (AAVs) to deliver therapeutic genes directly to the central nervous system (CNS) with remarkable efficacy and tolerability. Our innovative gene therapies hold the promise of not only halting disease progression but also restoring neurological function, offering hope to countless individuals and families affected by neurological disorders.
Harnessing the Power of AAVs
AAVs, nature's own delivery vehicles, have emerged as a powerful tool in gene therapy, offering a safe and efficient means to introduce therapeutic genes into target cells. Our proprietary AAV vectors are meticulously designed to navigate the complexities of the CNS, delivering the therapeutic cargo with precision and minimal disruption.
Restoring Myelin Integrity
Adrenoleukodystrophy (ALD), a devastating neurological disorder that affects both children and adults, is a prime target for our gene therapy approach. ALD is characterized by the progressive destruction of myelin, the protective sheath that surrounds nerve fibers, leading to severe neurological impairment. Our gene therapies aim to restore myelin integrity, halting disease progression and potentially reversing neurological deficits.
Revolutionizing Gene Therapy with Powerful Novel Vectors

Revolutionizing Gene Therapy with Powerful Novel Vectors

The promise of vectorized gene therapy has ignited a beacon of hope for people battling debilitating central nervous system (CNS) proteinopathies and rare neurological diseases. Our groundbreaking pipeline spearheaded by novel vectorized gene therapy is poised to halt disease progression and restore function.
At the forefront of our efforts are two devastating CNS diseases – 4H Leukodystrophy and Early Onset Parkinson’s Disease (EOPD). For 4H Leukodystrophy, a rare pediatric disease, we are developing LNP-mRNA therapies which deliver mRNAs that code for therapeutic functional proteins which instruct cells to produce beneficial proteins. Upregulating expression of the PINK1 and/or Parkin genes and clearing toxic protein are the goals of our EOPD therapy which leverages our proprietary vectorized nanoantibody platform.
Our Pipeline
Our gene therapy pipeline explores novel vectors and next-gen combination therapies with a focus on developing transformative treatment platforms for a wide spectrum of neurological disorders and aggressive cancers. We are committed to translating our cutting-edge research into clinical applications, bringing hope to patients and their families who have long awaited effective treatments.
Join Us in Changing Lives
Join us in our mission to revolutionize gene therapy and transform the lives of individuals affected by neurological disorders and rare diseases. Your support will fuel our research and development efforts, bringing us closer to a future where these debilitating conditions can be cured and lives are restored.Together, we can make a difference.
CNS Proteinopathy

CNS Proteinopathy

Neurological Disease

Neurological Disease

Meet Our

Our Team

With global industry experience, our team values collaboration, shares a passion for finding solutions to life’s biggest challenges and a desire to unlock the power of microRNA to transform healthcare for all.

Raj Reddy

CEO & President, Founder

View Details

Anna Wang

Senior Vice-President - Corporate Affairs & Partnerships, Co-Founder

View Details

Dr. Guangping Gao, PhD

Senior Scientific Advisor, Gene Therapy and Rare Diseases

View Details

Dr. Purav Badani

Head Scientist

View Details

Claire Henchcliffe, MD, D.Phil

Senior Medical Advisor, Neurological Disorders, Parkinson’s Disease

View Details

Dr Christine Duncan

Senior Scientific and Medical advisor , Rare Neurological Disease

View Details

Dr Troy Lund

Senior Scientific and Medical advisor , Rare Neurological Disease

View Details

Dr. Sanjay Gandhi

MD Senior Medical Advisor

View Details
Revolutionizing Alzheimer's Treatment with a One-Dose Gene Therapy
Alzheimer’s disease, a neurodegenerative disorder characterized by the accumulation of toxic proteins in the brain, has long been a formidable challenge for researchers and clinicians. Current treatment options offer limited relief, managing symptoms rather than addressing the underlying causes of the disease.
At Canary, we are poised to revolutionize Alzheimer’s treatment with a groundbreaking one-dose gene therapy. Our unique approach combines the addition of a functional transgene to replace a dysfunctional gene with a functional transgene as well as adding another transgene that empowers the body to produce targeted antibodies against toxic proteins. This combinatorial strategy offers a game-changing advantage, enabling us to simultaneously address both genetic defects and the pathological hallmarks of Alzheimer’s disease. Join us in pioneering a new era of Alzheimer’s care. Our innovative gene therapy has the potential to transform the lives of millions affected by this devastating disease.

Latest Updates

Our Commitment

We are committed to advancing the field of gene therapy and improving the lives of patients worldwide. Our team of scientists, engineers, and clinicians is dedicated to: